AAHRPP Accredits Three More Research Organizations
WASHINGTON, D.C.âThe Association for the Accreditation of Human Research Protection Programs (AAHRPP) announced that it has accredited three more research organizations, including its first in Hawaii-the 10-campus University of Hawaii System.
The newly accredited organizations are:
- Broad Institute of MIT and Harvard, Cambridge, Massachusetts
- Central Michigan University, Mount Pleasant, Michigan
- University of Hawaii System, Honolulu, Hawaii
“Today we welcome a biomedical and genomic research center, a public research university, and a statewide university system-all of which will have stronger research protection programs because of their commitment to AAHRPP’s high standards,” AAHRPP President and CEO Elyse I. Summers said. “With these latest accreditations, once again we demonstrate the universal application and value of AAHRPP accreditation.”
To date, 241 organizations-including 45 international entities-have earned AAHRPP accreditation. Accredited organizations must show that they have built extensive safeguards into every level of their research operation and that they adhere to high standards for research. In today’s global, collaborative research enterprise, organizations increasingly rely on AAHRPP accreditation status to help identify trusted research partners.
AAHRPP has accredited organizations across the United States and in Belgium, Brazil, Canada, China, India, Mexico, Republic of Korea, Saudi Arabia, Singapore, South Africa, Taiwan and Thailand. All major U.S. independent institutional review boards have earned AAHRPP accreditation. In addition, more than 60 percent of U.S. research-intensive universities and over 65 percent of U.S. medical schools are either AAHRPP accredited or have begun the accreditation process. The National Institutes of Health, the world’s largest public funder of research, has earned accreditation, as has Pfizer, Inc., the largest industry sponsor of clinical research.
About AAHRPP: A nonprofit organization, AAHRPP provides accreditation for organizations that conduct or review human research and can demonstrate that their protections exceed the safeguards required by the U.S. government. To learn more, visit here.
FOR MORE INFORMATION CONTACT:
Sarah Kiskaddon
Vice President, Global Development and Public Affairs
skiskaddon@aahrpp.org
(202) 783-1112
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
